research retatrutide Buy 10mg (Reta) Australia Retatrutide | Research Grade Peptide
Description
15 Months of Progress After 15 months of consistent treatment with Tirzepatide at a dose of 7.5 mg/week, JHs results were nothing short of inspiring: Follow-Up Bioimpedance Spectroscopy Measurements: Weight: 162 lbs (a 78-lb loss) Body Fat Percentage: 32.9% (down 12.8%) BMI: 23.3 (a reduction of 10.1 kg/m) Body Fat Mass: 53.2 lbs (a decrease of 56 lbs) Lean Body Mass: 109 lbs (down 21 lbs) Skeletal Muscle Mass: 59 lbs (loss of only 12 lbsjust 15% of her total weight loss, less than the typical 20%) ECW/TBW: Slight improvement in the right leg to 0.396
Additionally, GLP-1 agonists stimulate insulin secretion and decrease glucagon release, resulting in lower blood glucose levels
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unapproved by the MHRA, EMA, or FDA for routine clinical use
doi: 10.1016/j.cmet.2022.06.002
When done properly, compounding serves a vital public good, said Cook
doi: 10.1038/s41467-023-41893-4
